Clinical Developments and Challenges in Treating FGFR2-Driven Gastric Cancer

Area of Science:

• Oncology
• Molecular Biology
• Drug Development

Background:

• Metastatic gastric cancer (GC) has poor survival outcomes despite advances in treatment.
• Aberrant FGFR2 signaling, often due to FGFR2 amplification, is found in 3-11% of GCs.
• Currently, no approved therapies specifically target FGFR2 in GC.

Purpose of the Study:

• To review the significance of FGFR2 as a therapeutic target in GC.
• To examine pre-clinical and clinical data for FGFR2-directed therapies.
• To discuss challenges and opportunities in developing FGFR2-targeted treatments for GC.

Main Methods:

• Literature review of pre-clinical and clinical studies.
• Analysis of data on FGFR2 amplification in gastric cancer.
• Evaluation of various therapeutic strategies targeting FGFR2.

Main Results:

• FGFR2 amplification is a key driver in a subset of GC patients.
• Small-molecule inhibitors, antibody-based therapies, and PROTACs show promise for FGFR2 targeting.
• Clinical development of FGFR2-directed therapies for GC is ongoing.

Conclusions:

• FGFR2 represents a significant actionable target for GC treatment.
• Multiple therapeutic modalities are being investigated to target FGFR2 in GC.
• Further clinical development is crucial to overcome challenges and realize the potential of FGFR2-targeted therapies.